摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4-dimethyl-2-(3-thienyl)-2-oxazoline | 76505-62-9

中文名称
——
中文别名
——
英文名称
4,4-dimethyl-2-(3-thienyl)-2-oxazoline
英文别名
4,4-dimethyl-2-(3-thenyl)-2-oxazoline;4,4-dimethyl-2-(3-thienyl)-4,5-dihydrooxazole;4,4-dimethyl-2-(thiophen-3-yl)-2-oxazoline;2-(3-thienyl)-4,4-dimethyloxazoline;4,4-dimethyl-2-thiophen-3-yl-5H-1,3-oxazole
4,4-dimethyl-2-(3-thienyl)-2-oxazoline化学式
CAS
76505-62-9
化学式
C9H11NOS
mdl
——
分子量
181.258
InChiKey
DGBYNXUUEQRTGE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    59.5-60.5 °C(Solv: ligroine (8032-32-4))
  • 沸点:
    68-70 °C(Press: 0.4 Torr)
  • 密度:
    1.21±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    49.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Rationalisation of Patterns of Competing Reactivity by X-ray Structure Determination: Reaction of Isomeric (Benzyloxythienyl)oxazolines with a Base
    作者:R. Alan Aitken、Andrew D. Harper、Alexandra M. Z. Slawin
    DOI:10.3390/molecules26247690
    日期:——
    either Wittig rearrangement or intramolecular attack of the benzylic anion on the oxazoline function to give products derived from cleavage of the initially formed 3-aminothienofuran products. This pattern of reactivity is directly linked to the distance between the two reactive groups as determined by X-ray diffraction, with the greatest distance in 11 leading to exclusive Wittig rearrangement, the shortest
    三个异构体(benzyloxythienyl)恶唑啉9,11和13已被制备并发现,当治疗用强碱,接受对恶唑啉函数要么维蒂希重排或苄基阴离子的分子内攻击,得到从最初裂解衍生的产物形成3-氨基噻吩并产物。这种反应模式与通过 X 射线衍射确定的两个反应基团之间的距离直接相关,11 个中的最大距离导致唯一的 Wittig 重排,13 个中的最短距离仅提供环化衍生产物,中间体距离在9导致这两个过程都被观察到。在两种情况下也获得了相应的N-丁基酰胺,其中一种经过有效的 Wittig 重排,产生了噻吩并 [2,3- c ] 吡咯酮产物。
  • Palladium-Catalyzed Coupling of Oxazol-2-yl- and 2-Oxazolin-2-yltrimethylstannanes with Aromatic Halides. A New Entry to 2-Aryl and 2-Heteroaryl Oxazoles and Oxazolines
    作者:Alessandro Dondoni、Giancarlo Fantin、Marco Fogagnolo、Alessandro Medici、Paola Pedrini
    DOI:10.1055/s-1987-28047
    日期:——
    4-Methyloxazole and 4,4-dimethyl-2-oxazoline were treated with n-butyllithium and trimethyltin chloride to give the corresponding 2-trimethylstannyl derivatives which in the presence of tetrakis(triphenylphosphine)palladium(0) as a catalyst undergo cross-coupling reactions with various aryl and heteroaryl halides to give 2-aryl and 2-heteroaryl oxazoles and oxazolines in high yields.
    4-甲基恶唑和4,4-二甲基-2-恶唑啉用正丁基锂和三甲基氯化锡反应得到相应的2-三甲基甲锡烷基衍生物,在四(三苯基膦)钯(0)催化剂存在下发生交叉偶联与各种芳基和杂芳基卤化物反应,以高产率得到2-芳基和2-杂芳基恶唑和恶唑啉。
  • Secondary Phosphine Oxide Preligands for Palladium-Catalyzed C-H (Hetero)Arylations: Efficient Access to Pybox Ligands
    作者:Debasish Ghorai、Valentin Müller、Helena Keil、Dietmar Stalke、Giuseppe Zanoni、Boryslav A. Tkachenko、Peter R. Schreiner、Lutz Ackermann
    DOI:10.1002/adsc.201700663
    日期:2017.9.18
    C–H arylations of oxazolines were accomplished with a well‐defined palladium catalyst derived from a secondary bisdiamantyl phosphine oxide. The single‐component secondary phosphine oxide (SPO)‐palladium complex enabled C–H activations with aryl bromides and challenging aryl chlorides in the absence of directing groups, setting the stage for the step‐economical synthesis of pybox ligands under racemization‐free
    恶唑啉的C–H芳基化反应是使用衍生自仲双双金刚烷基氧化膦的明确定义的钯催化剂完成的。单组分仲氧化膦(SPO)-钯配合物可在没有引导基团的情况下用芳基溴化物和具有挑战性的芳基氯化物进行C-H活化,为在无消旋反应条件下逐步经济地合成pybox配体奠定了基础。
  • 3,6-disubstituted pyradazine derivatives
    申请人:Mitsubishi Chemical Corporation
    公开号:US05462941A1
    公开(公告)日:1995-10-31
    A 3,6-disubstituted pyridazine derivative having excellent platelet agglutination inhibitory effects. It is useful for a preventive medicine or a therapeutic medicine for a cerebrovascular disorder such as cerebral thrombosis and cerebral embolism, an ischemic heart disease such as myocardial infarction, and a circulation disorder such as peripheral circulation disorder. A pharmaceutical composition containing a compound of the present invention as an effective ingredient and a process for preparing the same are also disclosed. The compound has the formula (I) ##STR1## wherein A represents an alkyl group having 3 to 6 carbon atoms; a cycloalkyl group having 5 to 7 carbon atoms; a phenyl group, a thienyl group, a furyl group, a thiazolyl group, a phenoxy group, a phenylalkyl group having 7 to 9 carbon atoms, a phenylthio group, a 5-6 membered saturated heterocyclic group containing one or more nitrogen atoms, a pyridyl group or an imidazolyl group each of which may have at least one substituent selected from the group consisting of an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms and a halogen atom; B represents (a) --NH--D wherein D represents ##STR2## (4) --CH.sup.3 R.sup.4 ; or (5) an alkyl group having 3 to 8 carbon atoms; or ##STR3## and the ring C represents a benzene ring.
    一种具有出色的血小板凝聚抑制作用的3,6-二取代吡啶嗪衍生物。它可用于预防或治疗脑血栓和脑栓塞等脑血管疾病,心肌梗死等缺血性心脏病以及外周循环障碍等循环系统疾病的预防性或治疗性药物。本发明还公开了一种含有该化合物作为有效成分的制药组合物以及其制备方法。该化合物的化学式为(I)其中,A代表具有3到6个碳原子的烷基;具有5到7个碳原子的环烷基;苯基,噻吩基,呋喃基,噻唑基,苯氧基,具有7到9个碳原子的苯基烷基,苯硫基,含有一个或多个氮原子的5-6成员饱和杂环基,吡啶基或咪唑基,其中每个基团都可以具有至少一个选自由1到4个碳原子的烷基,1到4个碳原子的烷氧基和卤素原子的取代基;B代表(a)--NH--D,其中D代表##STR2##(4)--CH3R4;或(5)具有3到8个碳原子的烷基;或##STR3##环C代表苯环。
  • Synthesis, Structure, and Unusual Reactivity of a Stable 3-(Oxazolidin-2-ylidene)thiophen-2-one
    作者:R. Alan Aitken、Andrew D. Harper、Alexandra M. Z. Slawin
    DOI:10.1021/acs.joc.6b01309
    日期:2016.11.4
    that exist mainly as the oxazolidinylidenethiophenones. The 3-oxazolidinylidenethiophen-2-one is a rare example of a stable heterocyclic o-quinone methide analogue that shows a varied pattern of reactivity, including both C- and O-alkylation, Michael addition via C-5 to an acetylenic ester, tetrachlorobenzannulation across positions 4 and 5, and formation of a hexacyclic fused-ring product with N-
    用丁基锂和双(三甲基甲硅烷基)过氧化物处理2-和3-噻吩基恶唑啉可导致环羟基化,生成的产物主要为恶唑烷基亚叉基噻吩。3-恶唑烷亚叉基噻吩-2-酮是一种稳定的杂环邻醌甲基化物类似物的稀有实例,其表现出变化的反应模式,包括C-和O-烷基化,通过C-5的迈克尔加成至炔属酯,四氯苯甲酰化跨越位置4和5,并与N-苯基三唑啉二酮形成六环稠环产物。产物的晶体结构以分子间和分子内NH与CO的氢键为主。
查看更多

同类化合物

(4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] 香豆素-6-羧酸 锌离子载体IV 钐(III) 离子载体 II 苯,(2,2-二氟乙烯基)- 聚二硫二噻唑烷 缩胆囊肽9 甲酰乙内脲 甲巯咪唑 甲基羟甲基油基噁唑啉 甲基5-羟基-3,5-二甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-氰基-4,5-二氢-1,2-恶唑-3-羧酸酯 甲基5-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-5-氧代-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4,5-二氮杂螺[2.4]庚-5-烯-6-羧酸酯 甲基4,5-二氢-5-乙基-1H-吡唑-1-羧酸酯 甲基(E)-3-[6-[1-羟基-1-(4-甲基苯基)-3-(1-吡咯烷基)丙基]-2-吡啶基]丙烯酰酸酯 甲基(5-氧代-4,5-二氢-1,2-恶唑-3-基)乙酸酯 环戊二烯并[d]咪唑-2,5(1H,3H)-二硫酮 溶剂黄93 溴化1-十六烷基-3-甲基咪唑 溴化1-十二烷基-2,3-二甲基咪唑 泰比培南酯中间体 泰比培南酯中间体 氨基甲硫酸,[2-[[(2-羰基-1-咪唑烷基)硫代甲基]氨基]乙基]-,O-甲基酯 异噻唑,4,5-二氯-2,5-二氢-2-辛基- 希诺米啉 四氟硼酸二氢1,3-二(叔-丁基)-4,5--1H-咪唑正离子 四唑硝基紫 噻唑丁炎酮 噻唑,4,5-二氢-4-(1-甲基乙基)-,(S)- 噁唑,4,5-二氢-4,4-二甲基-2-(5-甲基-2-呋喃基)- 噁唑,2-庚基-4,5-二氢- 咪唑烷基脲 吡嗪,2,3-二氢-5,6-二甲基-2-丙基- 叔-丁基3-羟基-1,4,6,7-四氢吡唑并[4,3-c]吡啶-5-羧酸酯 双吡唑啉酮 双[(S)-4-异丙基-4,5-二氢噁唑-2-基]甲烷 双((R)-4-(叔丁基)-4,5-二氢恶唑-2-基)甲烷 利美尼啶D4 利美尼啶 假硫代乙内酰脲 依达拉奉杂质DO 依达拉奉杂质 依达拉奉三聚体 依达拉奉 仲班酸